Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30962501 | 0.83 | FGFR1 (0.50) | KMT2AMEN1GFERFGFR1 | |
| SCHEMBL2143624 | 0.83 | FGFR1 (0.50) | KMT2AMEN1GFERFGFR1 | |
| SCHEMBL27472868 | 0.81 | KMT2A (0.43) | GPR119KMT2AAURKACDK2MEN1 | |
| SCHEMBL20239526 | 0.79 | CHRNA7 (0.42) | MLYCDKMT2AFGFR1 | |
| SCHEMBL29809047 | 0.79 | CHRNA7 (0.42) | MLYCDKMT2AFGFR1 | |
| SCHEMBL14852045 | 0.78 | MAPT (0.44) | GPR119KMT2AMEN1FGFR1 | |
| SCHEMBL832385 | 0.77 | BRD4 (0.40) | GPR119KMT2AMEN1GFER | |
| SCHEMBL4816124 | 0.77 | GABRG2 (0.47) | KMT2AMEN1GFERHTR6 | |
| SCHEMBL7479053 | 0.77 | HTR6 (0.44) | KMT2AMEN1GFERHTR6FGFR1 | |
| SCHEMBL1417834 | 0.77 | ACSS2 (0.46) | GPR119KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | GPR119 2675/4885MLYCD 3764/4885KMT2A 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.